Search Results

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced it does not have direct exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank.

Immix Biopharma, Inc., a biopharmaceutical company pioneering Tissue-Specific Therapeutics ™ targeting oncology and immuno-dysregulated diseases, confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank or Silvergate Bank.

Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that neither Lantern Pharma Inc. nor any of its subsidiaries had any exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

CutisPharma, Inc. announced its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.

Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.

Journal is the official publication of the International Union of Immunological Societies